Early Vasopressin
Phase 3Small molecule
Early Vasopressin is one of 20 small molecule programs targeting Sepsis. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
19
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
308 competitors in Sepsis
#DrugCompanyPhaseTrials
1Early Vasopressin
HHospital do Coracao
Phase 3
Zyvox
PfizerPreclinical
Brevibloc
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Levophed
GGeneral Hospital of Ningxia Medical University
Preclinical
Jardiance
Boehringer IngelheimPreclinical
Micardis
Boehringer IngelheimPreclinical
Achromycin V
WWyeth-Lederle Vaccines
Preclinical
Levaquin
WWim Janssens
Preclinical
Pitocin
RRetrophin
Preclinical
Nacl
BayerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Early Vasopressin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- HHospital do Coracao